For this latest round of awards, MDA reviewed 187 applications and had sufficient funds to approve funding for approximately 15 percent of them — 29 grants with a total funding commitment of more than $7 million.
Over the past 35 years, the MDA Shamrocks program has raised more than $300 million to help save and improve the lives of families living with muscular dystrophy. Get to know Maya, who graces the 2017 green MDA Shamrock.
The FDA has approved Marathon Pharmaceuticals’ new drug applications for deflazacort (brand name Emflaza) to treat Duchenne Muscular Dystrophy
On Dec. 23, 2016 the FDA approved Spinraza for the treatment of SMA. In clinical trials to test Spinraza, participants who received treatment with the drug experienced life-changing outcomes they wouldn’t have been expected to achieve.
Strength, Science, and Stories of Inspiration (SSSI) and the Muscular Dystrophy Association (MDA) announced a new research funding mechanism for graduate students and postdoctoral trainees working in the muscle disease field.
Encouraging results from an MDA-supported study, have revealed a potential new strategy to treat spinal muscular atrophy (SMA).
Researchers are looking for people with ALS to participate in a research study aimed at better understanding the specific form of ALS caused by a mutation in the gene for C9ORF72.
The U.S. Food and Drug Administration (FDA) has approved Biogen’s nusinersen (brand name Spinraza) for the treatment of spinal muscular atrophy (SMA).
MDA began 2016 with an ambitious blueprint, full of changes and improvements — all designed to help us fulfill our mission promise to free individuals and families from the harmful effects of muscular dystrophy and related life-threatening diseases. Now, we reflect on our accomplishments and give thanks to our supporters.
Osaka-based Mitsubishi Tanabe Pharma has reported encouraging 12-month efficacy and safety data for edaravone (brand name Radicava) for the treatment of ALS. Edaravone is delivered by intravenous injection. It’s thought to work by relieving the effects of oxidative stress, which, in people with ALS, has been suspected to play a role in the death of . . .
